June 6, 2025

June 9, 2025

This week’s newsletter included:

• Recap of Australia Clinical Trials Event
• Rep. Kennedy Highlights Utah’s Life Sciences Industry at Committee Hearing
• Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for MDS
• VETFIRE: bioMerieux Launches Cutting-edge Equine Infectious Respiratory Disease Testing
• Arcutis’ ZORYVE (roflumilast) Topical Foam 0.3% Approved by FDA
• Renalytix Growing Collaboration with New York Kidney & Hypertension Medicine
• CancerVax Launches New StartEngine Fundraising Campaign
• CanverVax’s New Chief Scientific Officer, Dr. George Katibah
• CancerVax Scientists Featured on Cytiva’s Discovery Matters Podcast Discussing Universal Cancer Vaccine Platform
• Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
• Don’t Miss BioUtah’s Exclusive Biosphere Magazine Promotional Opportunity
• University of Utah Founders Day Distinguished Alumni Awards
• Utah Business: Nominations for Innovation Awards Open

Featured New BioUtah Elite Bronze Member: AstraZeneca